Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Answer from: at Academic Institution
My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.
Sign in or Register to read more
Answer from: at Community Practice
Six months after the last injection.
Sign in or Register to read more
Answer from: at Community Practice
Yes, 6 months after last Prolia shot. I give 2 doses of Zoledronic 1 year apart and then consider drug holiday based on the DEXA report.
Sign in or Register to read more
24261
24290
25967
Related Questions
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
How do you approach management of osteoporosis in patients post lung transplant?
Is there any evidence regarding bone density gains/fracture reduction in the setting of treatment with romosozumab after a two year course of teriparatide?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?